SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

米国の爪真菌症市場

米国の爪真菌症市場：規模、動向、予測（2021-2025年版）The US Onychomycosis Market: Size, Trends & Forecasts (2021-2025 Edition)

このレポートへお問合せ

  
種別英文調査報告書
出版Daedal Research
出版年月2021年5月
ページ数70
図表数
価格（USD）
シングルユーザライセンス850
エンタープライズライセンス1400
 

レポート目次

  Report DetailsScope of the ReportThe report entitled “The US Onychomycosis Market: Size, Trends & Forecasts (2021-2025 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size in terms of value, volume and segments. The report also includes the analysis of the larger nail care market in order to showcase the position of onychomycosis with respect to the nail care industry.Under competitive landscape, different players in the onychomycosis industry have been compared on the basis of parameters such as revenue and market capitalization.Bausch Health Companies (Formerly Valeant Pharmaceuticals), Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.Company CoverageBausch Health Companies (Formerly Valeant Pharmaceuticals)Pfizer, Inc.Johnson and JohnsonNovartis AGExecutive SummaryThere are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.The US onychomycosis market is forecasted to grow at a healthy growth rate during the forecast period (2021-2025). The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc. Table of Contents1. Executive Summary2. Introduction2.1 Onychomycosis: An Overview2.1.1 Signs and Symptoms2.1.2 Causes of Onychomycosis2.2 Types of Onychomycosis2.3 Treatment for Onychomycosis3. Global Market Analysis3.1 Global Nail Care Market: An Analysis3.1.1 Global Nail Care Market by Value3.1.2 Global Nail Care Market by Segment (Onychomycosis (Antifungal Medications and Non Pharmacological Products) and Other Nail Care Products)3.2 Global Onychomycosis Market: An Analysis3.2.1 Global Onychomycosis Market by Value3.2.2 Global Onychomycosis Market by Segment (Kerydin, Jublia and other non pharmacolgic treatments)3.3 Global Onychomycosis Market: Segment Analysis3.3.1 Global Kerydin Drugs Market by Value3.3.2 Global Jublia Drugs Market by Value3.4 Global Onychomycosis Market: Pipeline Drugs Analysis3.4.1 Phase II Drugs (Onychomycosis) Pipeline Forecast3.4.2 Phase III Drugs (Onychomycosis) Pipeline Forecast3.5 Onychomycosis Market: New Drugs Overview3.6 Global Onychomycosis Market: Country Analysis3.6.1 Global Onychomycosis Market by Countries (The US and ROW)4. The US Market Analysis4.1 The US Nail Care Market: An Analysis4.1.1 The US Nail Care Market by Value4.1.2 The US Nail Care Market by Segments Segment (Onychomycosis (Antifungal Medications and Non Pharmacological Products) and Other Nail Care Products)4.2 The US Onychomycosis Market: An Analysis4.2.1 The US Onychomycosis Market by Value4.3 The US Onychomycosis Market: Type of Treatment Analysis4.3.1 The US Onychomycosis Market by Type of Treatment (Pharmacological and Non Pharmacological)4.3.2 The US Pharmacological Onychomycosis Market by Value4.3.3 The US Pharmacological Onychomycosis Market by Route of Administration4.3.4 The US Topical Onychomycosis Market by Value4.3.5 The US Oral Onychomycosis Market by Value4.4 The US Onychomycosis Market: Drug Availability Analysis4.4.1 The US Pharmacological Onychomycosis Market by Drug Availability4.5 The US Onychomycosis Market: Prescription Drugs Analysis4.5.1 The US Prescription Onychomycosis Drugs Market by Value4.5.2 The US Prescription Onychomycosis Market Value by Product (Jubila and Kerydin)4.6 The US Onychomycosis Market: OTC Drugs Analysis4.6.1 The US OTC Onychomycosis Drugs Market by Value5. Competitive Landscape5.1 Competition in Onychomycosis Prescription Market: An Overview5.2 Financial Comparison of Major Players of the US Onychomycosis Market6. Company Profiles6.1 Bausch Health Companies (Formerly Valeant Pharmaceuticals)6.1.1 Business Overview6.1.2 Financial Overview6.1.3 Business Strategy6.2 Pfizer Inc.6.2.1 Business Overview6.2.2 Financial Overview6.2.3 Business Strategy6.3 Johnson & Johnson6.3.1 Business Overview6.3.2 Financial Overview6.3.3 Business Strategy6.4 Novartis AG6.4.1 Business Overview6.4.2 Financial Overview6.4.3 Business StrategyList of FiguresFigure 1: Types of OnychomycosisFigure 2: Treatment for OnychomycosisFigure 3: Global Nail Care Market by Value; 2017-2020 (US$ Billion)Figure 4: Global Nail Care Market by Value; 2021-2025 (US$ Billion)Figure 5: Global Nail Care Market by Segments; 2020 (Percentage, %)Figure 6: Global Onychomycosis Market by Value; 2017-2020 (US$ Billion)Figure 7: Global Onychomycosis Market by Value; 2021-2025 (US$ Billion)Figure 8: Global Onychomycosis Market by Segments; 2020 (Percentage, %)Figure 9: Global Kerydin Drugs Market by Value; 2017-2020 (US$ Million)Figure 10: Global Kerydin Drugs Market by Value; 2021-2025 (US$ Million)Figure 11: Global Jublia Drugs Market by Value; 2017-2020 (US$ Million)Figure 12: Global Jublia Drugs Market by Value; 2021-2025 (US$ Million)Figure 13: Phase II Drugs (Onychomycosis) Pipeline Forecast; 2021-2026 (US$ Million)Figure 14: Phase III Drugs (Onychomycosis) Pipeline Forecast; 2018-2026 (US$ Million)Figure 15: Global Onychomycosis Market by Countries; 2020 (Percentage, %)Figure 16: The US Nail Care Market by Value; 2017?2020 (US$ Billion)Figure 17: The US Nail Care Market by Value; 2021?2025 (US$ Billion)Figure 18: The US Nail Care Market by Segments; 2020 (Percentage, %)Figure 19: The US Onychomycosis Market by Value; 2017?2020 (US$ Billion)Figure 20: The US Onychomycosis Market by Value; 2021?2025 (US$ Billion)Figure 21: The US Onychomycosis Market by Type of Treatment; 2020 (Percentage, %)Figure 22: The US Pharmacological Onychomycosis Market by Value; 2017-2020 (US$ Billion)Figure 23: The US Pharmacological Onychomycosis Market by Value; 2021-2025 (US$ Billion)Figure 24: The US Pharmacological Onychomycosis Market by Route of Administration; 2020 (Percentage, %)Figure 25: The US Topical Onychomycosis Market by Value; 2017-2020 (US$ Billion)Figure 26: The US Topical Onychomycosis Market by Value; 2021-2025 (US$ Billion)Figure 27: The US Oral Onychomycosis Market by Value; 2017-2020 (US$ Billion)Figure 28: The US Oral Onychomycosis Market by Value; 2021-2025 (US$ Billion)Figure 29: The US Pharmacological Onychomycosis Market by Drug Availability; 2020 (Percentage, %)Figure 30: The US Prescription Onychomycosis Drugs Market by Value; 2017-2020 (US$ Billion)Figure 31: The US Prescription Onychomycosis Drugs Market by Value; 2021-2025 (US$ Billion)Figure 32: The US Prescription Onychomycosis Market Value by Product; 2020 (Percentage, %)Figure 33: The US OTC Onychomycosis Drugs Market by Value; 2017-2020 (US$ Million)Figure 34: The US OTC Onychomycosis Drugs Market by Value; 2021-2025 (US$ Million)Figure 35: Bausch Health Companies; 2016-2020 (US$ Billion)Figure 36: Bausch Revenue by Segments; 2020 (Percentage, %)Figure 37: Bausch Revenue by Region; 2020 (Percentage, %)Figure 38: Pfizer Inc. Revenue; 2016-2020 (US$ Billion)Figure 39: Pfizer Inc. Revenue by Region; 2020 (Percentage, %)Figure 40: Johnson & Johnson Total Sales; 2016-2020 (US$ Billion)Figure 41: Johnson & Johnson Total Sales by Segments; 2020 (Percentage, %)Figure 42: Johnson & Johnson Total Sales by Region; 2020 (Percentage, %)Figure 43: Novartis AG Business SegmentsFigure 44: Novartis AG Net Sales; 2016-2020 (US$ Billion)Figure 45: Novartis AG Net Sales by Segment; 2020 (Percentage, %)Figure 46: Novartis AG Net Sales by Region; 2020 (Percentage, %)Table 1: Treatments Available for OnychomycosisTable 2: Financial Comparison of Major Players of the US Onychomycosis Market
お問合せフォーム

    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com

    プライバシーポリシーはこちらをご覧ください。

    その他の最新記事8件